Editing Upper Urinary Tract Urothelial Cancer (section)

==== Schedule ====

===== AUA =====

* '''See [https://www.auanet.org/images/Guidelines/Guideline%20Images/UTUC%202023/Table%206%20UTUC%20Word%20Version.jpg Table] from Original Guidelines'''

====== Surveillance after kidney sparing ======
*'''Low-risk patients managed with kidney sparing treatment'''
**'''Cystoscopy and upper tract endoscopy within 1-3 months of treatment to confirm successful treatment.'''
**If successful treatment confirmed (no evidence of disease), perform
***Cystoscopy of the bladder once again within the first year after treatment, then at least every 6-9 months for the first 2 years and then at least annually thereafter.
**** Upper tract endoscopy at 6 months and 1 year [after treatment].
*****Can be subsequently performed for any symptoms or significant findings on upper tract imaging.
****Upper tract imaging should be performed at least every 6-9 months for first 2 years, then annually up to 5 years.
****Surveillance after 5 years in the absence of recurrence should be based on shared decision-making.
**No distant metastatic evaluation since risk is low with low-risk disease
*'''High-risk patients managed with kidney sparing treatment'''
**'''Cystoscopy, upper tract endoscopy, and upper tract urine cytology within 1-3 months of treatment to confirm successful treatment.'''
**If successful treatment confirmed (no evidence of disease), perform
***Cystoscopy of the bladder and cytology at least every 3-6 months for the first 3 years and then every 6-12 months up to 5 years.
***Upper tract endoscopy should be performed at least at 6 months and 1 year [after treatment]
***Upper tract imaging and BMP should be performed every 3-6 months for 3 years, then every 6-12 months for 2 years, and then annually thereafter.
***Distant metastatic evaluation: Chest imaging (chest X-ray or CT) is recommended every 6-12 months to evaluate for intrathoracic metastasis up to 5 years following last diagnosis/treatment
***Surveillance after 5 years in the absence of recurrence should be based on shared decision-making.
*'''If patient develops urothelial recurrence in the bladder or urethra or positive cytology following kidney sparing treatment for UTUC, evaluate for possible ipsilateral recurrence or development of new contralateral upper tract disease.'''
======Surveillance after radical nephroureterectomy ======
*'''<pT2 N0/M0 managed with NU'''
**Cystoscopy and urine cytology within 3 months after surgery, then repeated based on pathologic grade.
***For LG this should repeated at least every 5-9 months for the first 2 years and then at least annually thereafter.
***For HG, this should be repeated at least every 3-6 months for the first 3 years and then at least annually thereafter.
**Cross-sectional imaging of the abdomen and pelvis should be done within 6 months after surgery and then at least annually for a minimum of 5 years***Due to the metastasis risk and estimated 5% probability for contralateral disease
***Follow up after nephroureterectomy for patients with non-muscle invasive, node-negative UTUC should be largely focused on the risk of intravesical recurrence
** Surveillance after five years in the absence of recurrence should be encouraged and based on shared decision-making between the patient and clinician
*'''T2+ managed with NU'''
**Cystoscopy with cytology at 3 months after surgery, then every 3-6 months for 3 years, and then annually thereafter.
**Cross-sectional imaging of the abdomen and pelvis with multiphasic contrast-enhanced CT urography should be performed every 3-6 months for years 1 and 2, every 6 months at year 3, and annually thereafter to year 5.
**Chest imaging, preferably with chest CT, every 6-12 months for the first 5 years.
**Beyond five years after surgery in patients without recurrence, ongoing surveillance with cystoscopy and upper tract imaging may be continued on an annual basis according to principles of shared/informed decision-making
*'''Sequelae of nephroureterectomy'''
**'''Repeat assessment of blood pressure, eGFR, and proteinuria should be performed soon after nephroureterectomy then again in 3-6 months to assess for development or progression of CKD.'''
***With significant nephron mass loss, hyperfiltration can occur resulting in glomerular damage, exacerbation of proteinuria and progressive sclerosis with further decline in GFR.
*** The long-term impact of renal dysfunction increases risks of osteoporosis, anemia, metabolic and cardiovascular disease, hospitalization and death.
***Effective treatment strategies are available to slow the progression of CKD and reduce cardiovascular risks, and therefore timely identification of progressive renal dysfunction and/or proteinuria can provide opportunity for medical intervention when indicated.
****Careful management of DM and HTN and avoidance of substantial weight gain may slow or prevent CKD progression and should be prioritized on a long-term basis
****Identifying modifiable risk factors including diabetes mellitus (DM), hypertension (HTN) and smoking is essential. Optimizing glycemic and blood pressure control, smoking cessation and minimizing risk of acute kidney injury (with avoidance of hypotension and nephrotoxic agents such as intravenous contrast or non-steroidal anti-inflammatory drugs) should reduce the degree of renal dysfunction in the perioperative period.
***'''In patients who develop progressive renal insufficiency or proteinuria should be referred to nephrology.'''
**Other laboratory evaluations (e.g., CBC, LDH, liver function tests, and alkaline phosphatase) may be obtained at the discretion of the clinician or if advanced disease is suspected.

===== CUA =====

*'''See [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114151/table/t6-cuaj-8-243/ Table] from [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114151/ 2018 CUA Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma]'''
*'''Bladder'''
** '''Should be assessed with cytology and cystoscopy in all patients at months 3, 6, 12, 18, 24 and annually thereafter for up to 10 years of recurrence-free survival'''
* '''<span style="color:#ff0000">Ipsilateral upper tract</span>'''
** '''<span style="color:#ff0000">Should be assessed by URS and selective cytology or biopsy in all patients following nephron-sparing procedures at months 3, 6, 12, 18, 24 and annually thereafter up to 10 years of recurrence-free survival</span>'''
*** '''<span style="color:#ff0000">Computed tomography urography (CTU) and retrograde pyelography lacks sensitivity</span>'''
* '''Extra-urinary sites'''
** '''<span style="color:#ff0000">Routine blood work should include:</span>'''
*** '''<span style="color:#ff0000">Renal function tests</span>'''
*** '''<span style="color:#ff0000">Metabolic panel, including liver function tests, calcium and alkaline phosphatase</span>'''
** '''<span style="color:#ff0000">To assess for local, contralateral and distant metastases</span>''' in patients after nephroureterectomy or nephron-sparing procedures, '''<span style="color:#ff0000">imaging of the abdomen and pelvis with CTU is recommended</span>'''
*** MRI or US may be substituted for CTU in patients with contraindications to CTU
*** '''CXR is recommended to assess for lung metastases'''
*** Bone scan is indicated in the presence of bone pain, elevated calcium or elevated alkaline phosphatase to assess for bone metastases
* '''Lack of evidence for an optimal duration of surveillance; recommended approach:'''
** '''High-grade, pT≥2 or pN+: lifelong annual surveillance with history, physical examination, blood work, urine cytology and abdominal/chest imaging'''
** '''Low-grade, pT<2 pN0/x: annual cystoscopy and ipsilateral ureteroscopy (following nephron-sparing procedures) may be omitted after 10 years of recurrence-free survival; after 10 years of recurrence-free survival, patients with may be discharged from annual surveillance'''